Teppo J. Huttunen
Turku, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs.
Journal: Expert review of anticancer therapy
Published: February 28, 2026
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.
Journal: BMJ oncology
Published: March 14, 2025
Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial.
Journal: European urology oncology
Published: February 17, 2025
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
Journal: JAMA network open
Published: August 26, 2024
Body movement as a biomarker for use in chronic pain rehabilitation: An embedded analysis of an RCT of a virtual reality solution for adults with chronic pain.
Journal: Frontiers in pain research (Lausanne, Switzerland)
Published: October 31, 2022
Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.
Journal: Critical care (London, England)
Published: October 17, 2022
Feasibility and patient acceptability of a commercially available wearable and a smart phone application in identification of motor states in parkinson's disease.
Journal: PLOS digital health
Published: May 24, 2022
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Journal: Anticancer research
Published: October 20, 2021
Effect of Bifidobacterium animalis spp. lactis Bl-04 on Rhinovirus-Induced Colds: A Randomized, Placebo-Controlled, Single-Center, Phase II Trial in Healthy Volunteers.
Journal: EClinicalMedicine
Published: July 05, 2021
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Journal: Anticancer research
Published: October 27, 2020
Last Updated: 09/26/2026